Tetraphase Pharmaceuticals, Inc. announced that the Board appointed Larry Edwards as President and Chief Executive Officer, effective August 1, 2019. Mr. Edwards, the Company's current Chief Operating Officer, will succeed Guy Macdonald, who will remain on the Board after August 1, 2019. The Board also approved an increase in the size of the Board from seven to eight and the election of Mr. Edwards to the Board effective August 1, 2019.

Mr. Edwards was elected as a Class I director to serve until the Company's 2020 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal. Mr. Edwards, age 47, has served as the Company's Chief Operating Officer since March 2018. From December 2016 to February 2018, Mr. Edwards served as the Company's Senior Vice President, Chief Commercial Officer and from January 2016 to December 2016 as the Company's Vice President, Commercial Operations.

On June 10, 2019, Larry Tsai, M.D. resigned from his position as the Company's Chief Medical Officer in order to pursue other interests. Dr. Tsai's resignation is effective June 24, 2019. The Company intends to conduct a search for a candidate to assume Dr. Tsai's duties.

In addition to the promotion of Mr. Edwards, Maria Stahl, Senior Vice President and General Counsel of Tetraphase, has been promoted to Chief Business Officer. In this new role, her responsibilities will include overseeing other corporate functions, including finance, business development and investor relations. The reorganization will also include the departure of Tetraphase's Chief Medical Officer, Larry Tsai, M.D. and Chief Scientific Officer, Jacques Dumas, Ph.D. Dr. Tsai has been an outstanding contributor to Tetraphase's development programs. Dr. Tsai is resigning his position effective June 24, 2019.

Dr. Dumas' position is being eliminated effective July 19, 2019. Dr. Dumas is expected to enter into a consulting relationship with the Company in order to support the out licensing of TP-2846, the Company's novel drug candidate for acute myeloid leukemia.